当前位置:首页 > 报告详情

再鼎 JPM 2025 Presentation_FULL_2025.01.14_FINAL FINAL.pdf

上传人: c** 编号:604000 2025-02-03 41页 2.63MB

1、NASDAQ:ZLAB|HKEX:9688 2025.Zai Lab.All Rights Reserved.January 14,2025|J.P.Morgan Healthcare ConferenceZai Lab Corporate PresentationSamantha Du,Ph.D.Founder,Chairperson and Chief Executive Officer of Zai LabForward-Looking StatementsThis presentation contains forward-looking statements relating to

2、our strategy and plans;potential of and expectations for ourbusiness,clinical development strategy,andpipeline programs;our goals and expectations under our growth strategy(including our expectations regarding our commercial-stage products,clinical-stage global-rightproducts,revenue growth/CAGR,prof

3、itability and timeline to profitability,operating margins,and cash flow);the peak sales potential of our programs;capital allocation andinvestment strategy;clinical development programs and related clinical trials;expected timing and results of clinical trial data,data readouts,and presentations;ris

4、ks anduncertainties associated with drug development,commercialization and outreach;regulatory discussions,submissions,filings,and approvals and the timing and scope thereof;the potential benefits,safety,and efficacy of our products and product candidates and those of our collaboration partners;the

5、expected benefits and potential ofinvestments,collaborations,and business development activities;the potential market opportunities of,and estimated addressable markets for,our drug candidates;our futurefinancial and operating results;and financial guidance.All statements,other than statements of hi

6、storical fact,included in this presentation are forward-looking statements,and can be identified by words such as“aim,”“anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“forecast,”“goal,”“intend,”“may,”“plan,”“possible,”“potential,”“target,”“will,”“would,”and other similar expressions.Su

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文是Zai Lab公司于2025年1月14日在摩根大通医疗保健会议上进行的公司介绍。主要内容包括: 1. 公司概况:Zai Lab是一家专注于创新药物研发的生物制药公司,拥有强大的研发管线和商业平台。 2. 2024年主要成就:公司收入增长48%,净亏损减少40%,现金储备达到约9.3亿美元。VYVGART®在重症肌无力(gMG)和慢性炎症性脱髓鞘多神经病(CIDP)领域取得成功,KarXT在精神分裂症领域取得积极III期试验结果。 3. 2025年计划:计划在中国提交KarXT和bemarituzumab的新药申请,并推进多个全球管线资产。 4. 未来增长:预计到2028年,公司将有超过15个产品上市,总收入达到20亿美元。 5. 财务状况:公司预计2025年底实现盈利,现金储备将支持业务发展和发现工作。 6. ESG战略:公司致力于通过ESG战略和多元化、公平、包容的承诺,为所有人创造更好的结果。
泽亚实验室如何实现盈利? 泽亚实验室的三大潜在重磅药物是什么? 泽亚实验室在ESG方面有哪些承诺和目标?
客服
商务合作
小程序
服务号
折叠